A within-subject analysis of carbamazepine disposition related to development in children with epilepsy.
The effect of aging on carbamazepine (CBZ) plasma level/dose ratio was evaluated retrospectively in 15 children who were receiving CBZ monotherapy and who were followed up for at least 3 years. Subjects of the study were selected from a population of roughly 4,500 patients attending our therapeutic drug monitoring service during a 12-year period. Results showed that the CBZ plasma level/dose ratio increases within subject during childhood, in agreement with data obtained in between-patient studies. However, the increase is not linear with age, the greatest modifications being observed between 9 and 13 years of age. Weight gain alone does not seem to explain this finding, implicating the involvement of complex physiological changes occurring during puberty.
Albani
F
F
Laboratory of Neuropharmacology, University of Bologna, Italy.
Riva
R
R
Contin
M
M
Baruzzi
A
A
D000293:Adolescent; D000375:Aging / Q000097:blood; D002220:Carbamazepine / Q000097:blood / Q000493:pharmacokinetics*; D002648:Child; D002657:Child Development / Q000502:physiology*; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring; D004827:Epilepsy / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D005260:Female; D006801:Humans; D008297:Male; D012189:Retrospective Studies; D015430:Weight Gain / Q000502:physiology
D002220:Carbamazepine